Biologics in organ transplantation.

Journal Article (Journal Article;Review)

The last two decades have witnessed a pandemic in antibody development, with over 600 entering clinical studies and a total of 28 approved by the FDA and European Union. The incorporation of biologics in transplantation has made a significant impact on allograft survival. Herein, we review the armamentarium of clinical and preclinical biologics used for organ transplantation--with the exception of belatacept--from depleting and IL-2R targeting induction agents to costimulation blockade, B-cell therapeutics, BAFF and complement inhibition, anti-adhesion, and anti-cytokine approaches. While individual agents may be insufficient for tolerance induction, they provide possibilities for reduction of steroid or calcineurin inhibitor use, alternatives to rejection episodes refractory to conventional therapies, and specialized immunosuppression for highly sensitized patients.

Full Text

Duke Authors

Cited Authors

  • Page, EK; Dar, WA; Knechtle, SJ

Published Date

  • July 2012

Published In

Volume / Issue

  • 25 / 7

Start / End Page

  • 707 - 719

PubMed ID

  • 22420711

Electronic International Standard Serial Number (EISSN)

  • 1432-2277

Digital Object Identifier (DOI)

  • 10.1111/j.1432-2277.2012.01456.x


  • eng

Conference Location

  • Switzerland